Osteoporosis in men

Treatment and prevention of postmenopausal osteoporosis glucocorticoid-induced osteoporosis osteoporosis in men Paget s disease... 

Alendronate should be considered hrst-line treatment for primary osteoporosis in men owing to its proven benefit in reducing fractures and relative safety. 

Compared with postmenopausal osteoporosis, few clinical trials have been conducted evaluating therapies in men. Although alendronate and calcitonin have both been studied, only alendronate reduces fracture rates in men. Teriparatide also has been studied, but no data are available yet on fracture rates. At this time, alendronate and teriparatide are approved by the FDA for the treatment of osteoporosis in men. Owing to proven benefit in reducing fractures and relative safety, alendronate should be considered first-line treatment for primary osteoporosis in men. Teriparatide should be reserved as alternate therapy in this population. 

Osteoporosis in men 10 mg once daily. Alternatively, one 70 mg tablet or 1 bottle of 70 mg oral solution once weekly may be considered. 

Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women a randomized trial. European Corticosteroid-Induced... 

Olszynski WP, Davison KS, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris ST, Hodsman AB, Kendler D, McClumg MR, Miller PD, Yuen CK. Osteoporosis in men epidemiology, diagnosis, prevention and treatment. ClinTher 2004 26 15-28. 

Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000 85(9) 3069-76. 

Tashjian AH Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002 17(7) 1151-61. 

Alendronate is licensed for the treatment of postmenopausal osteoporosis and osteoporosis in men, prevention of postmenopausal osteoporosis and the prevention and treatment of corticosteroid-induced osteoporosis. 

Calcitonin therapy is also used in the treatment of osteoporosis in men and women. Calcitonin is a hormone composed of 32 amino acids. It has a C-terminal amide group. Calcitonin is synthesized and secreted mainly by the thyroid gland and in much smaller amounts by other organs. Calcitonin occurs in the plasma at about 20 pg/ml. Osteoclasts contain calcitonin receptors. The hormone appears to impair the metabolic activity of the osteoclasts. The physiological function of... 

Olszynski WP, Shawn Davison K, Adachi ID, et al. Osteoporosis in men Epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004 26 15-28. 

Risedronate sodium is a bisphosphonate that inhibits normal and abnormal bone resorption. It is indicated in the treatment of osteoporosis in postmenopausal women the prevention of osteoporosis in postmenopausal women at risk of developing osteoporosis the prevention and treatment of glucocorticoid-induced osteoporosis in men and women and in the treatment of Paget s disease of the bone. 

---